what are the glp 1 drug names Letter: Association Between Incretin Mimetics and Medullary Thyroid Cancer GLP-1 Medications: What You Need

Description

PMID: 34215025

PubMed pubmed.ncbi.nlm.nih.gov [32] Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial ScienceDirect science/article/pii/S0140673624014983 [33] Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial ScienceDirect science/article/pii/S0140673624014983 [34] Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial PubMed pubmed.ncbi.nlm.nih.gov [35] Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial PubMed pubmed.ncbi.nlm.nih.gov [36] Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients ScienceDirect science/article/abs/pii/S0146280624000422 [37] Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients PubMed pubmed.ncbi.nlm.nih.gov [38] Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients PubMed pubmed.ncbi.nlm.nih.gov [39] Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics PubMed pubmed.ncbi.nlm.nih.gov [40] Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial PubMed pubmed.ncbi.nlm.nih.gov [41] Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial PubMed pubmed.ncbi.nlm.nih.gov [45] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes PubMed pubmed.ncbi.nlm.nih.gov [46] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial PubMed pubmed.ncbi.nlm.nih.gov [47] Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis PubMed pubmed.ncbi.nlm.nih.gov [48] Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis PubMed pubmed.ncbi.nlm.nih.gov [49] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial PubMed pubmed.ncbi.nlm.nih.gov [50] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes PubMed pubmed.ncbi.nlm.nih.gov [51] Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis ScienceDirect science/article/pii/S0753332224000313 [52] GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review ScienceDirect science/article/pii/S2589537024003614 [53] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes PubMed pubmed.ncbi.nlm.nih.gov [54] Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial PubMed pubmed.ncbi.nlm.nih.gov [55] Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis ScienceDirect science/article/pii/S0753332224000313 [56] GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review ScienceDirect science/article/pii/S2589537024003614 [57] GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)

In addition, many of these patients will have additional risk factors for delayed gastric emptying (for example, diabetes or obesity) which must be taken into consideration

The science of muscle hypertrophy: making dietary protein count

To experimentally ascertain the importance of Val 27 for GLP1R specific activity, we synthesized a new incretin agonist I-M-150846 where the C-terminal amino acids Val 27 -Gly 31 of I-M-150845 are substituted with 11-amino acid C terminus (Met 27 -Ala 37 ) of oxyntomodulin ( Figure1 supplementary Fig 4 )